HeartBeam has announced a strategic alliance agreement (SAA) with global tech giant Samsung.
The alliance, announced today, builds upon an existing SAA between Samsung and Livmor, whose assets HeartBeam acquired earlier this year.
Livmor created the FDA-cleared wearable Halo atrial fibrillation detection system — an FDA-cleared, Samsung-Galaxy-watch-based arrhythmia detection tool. Meanwhile, HeartBeam recently secured a pivotal patent related to artificial intelligence capabilities for its AIMIGo system — a personal, portable vector electrocardiogram (VECG) system. Also, this month, HeartBeam submitted AIMIGo for FDA 510(k) clearance.
This collaborative venture between HeartBeam and Samsung will explore opportunities to leverage HeartBeam’s proprietary technology and expertise in cardiac symptom assessment and monitoring. The two companies think their technologies could boost the standard of cardiac diagnostic capabilities.